{"id":"non-insulin-antihyperglycemic-drugs","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Weight changes"},{"rate":null,"effect":"Lactic acidosis (metformin-associated)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a broad drug class encompassing multiple mechanisms of action including sulfonylureas (stimulating pancreatic beta cells), biguanides like metformin (reducing hepatic glucose output and improving peripheral insulin sensitivity), DPP-4 inhibitors (prolonging GLP-1 action), SGLT2 inhibitors (promoting urinary glucose excretion), and thiazolidinediones (enhancing insulin sensitivity). Each subclass targets different pathophysiological aspects of type 2 diabetes.","oneSentence":"Non-insulin antihyperglycemic drugs lower blood glucose through mechanisms other than insulin replacement, such as enhancing insulin secretion, improving insulin sensitivity, or reducing hepatic glucose production.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:23:18.173Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06111508","phase":"NA","title":"The Effect and Safety of a Novel CGM-Based Titration Algorithm for Basal Insulin in T2DM Participants.","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2023-11-29","conditions":"Type 2 Diabetes","enrollment":30},{"nctId":"NCT04416269","phase":"PHASE4","title":"Oral Anti Diabetic Agents in the Hospital","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2020-08-07","conditions":"Diabetes Mellitus","enrollment":255},{"nctId":"NCT07265037","phase":"NA","title":"Integrated TCM - Western Medicine Strategy for Long - Distance Diabetes Management","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-11-01","conditions":"Diabetes Mellitus, Type 2, Integrated Traditional Chinese Medicine and Western Medicine, Telemedicine","enrollment":10000},{"nctId":"NCT05214573","phase":"","title":"Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2021-12-01","conditions":"Type 2 Diabetes, Cardiac Disease","enrollment":386301},{"nctId":"NCT04980027","phase":"PHASE4","title":"Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Drugs","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-06-07","conditions":"Type 2 Diabetes Mellitus","enrollment":228},{"nctId":"NCT05362058","phase":"PHASE3","title":"A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-06-03","conditions":"Diabetes, Type 2 Diabetes","enrollment":928},{"nctId":"NCT06946628","phase":"PHASE3","title":"New Triple Therapy in Newly Diagnosed Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-06-01","conditions":"Diabetes Mellitus","enrollment":296},{"nctId":"NCT05699408","phase":"PHASE3","title":"To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-03-31","conditions":"Type 2 Diabetes","enrollment":513},{"nctId":"NCT06125587","phase":"PHASE2, PHASE3","title":"Chiglitazar/Metformin in Non-obese Women With PCOS","status":"COMPLETED","sponsor":"Shengjing Hospital","startDate":"2023-11-15","conditions":"Polycystic Ovary Syndrome, Chiglitazar, Metformin","enrollment":55},{"nctId":"NCT06725238","phase":"","title":"Acute-to-chronic Glycemic Ratio (ACGR) is a Marker of DFUs .","status":"COMPLETED","sponsor":"University of Diyala","startDate":"2024-05-01","conditions":"Diabetic Foot Ulcer (DFU)","enrollment":80},{"nctId":"NCT03418779","phase":"PHASE2, PHASE3","title":"Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","startDate":"2019-07-04","conditions":"IgA Nephropathy at High Risk of Developing ESRD","enrollment":60},{"nctId":"NCT04017221","phase":"","title":"Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients with Type 2 Diabetes","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2018-10-01","conditions":"Diabetes Mellitus, Type 2, Urosepsis, Diabetic Ketoacidosis","enrollment":1249636},{"nctId":"NCT02002091","phase":"","title":"Morbidity in Newly Diagnosed type2 Diabetes in Adults","status":"COMPLETED","sponsor":"University of Algiers","startDate":"2009-01","conditions":"Type2 Diabetes Mellitus, Complications","enrollment":327},{"nctId":"NCT05284344","phase":"","title":"The Impact of Glucotoxicity on Gastric Emptying in Chinese Patients With Newly Diagnosed Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Adelaide","startDate":"2021-01-24","conditions":"Type 2 Diabetes","enrollment":78},{"nctId":"NCT06280729","phase":"","title":"AI-Predicted Disease Trajectories in Diabetes: A Retrospective Study","status":"UNKNOWN","sponsor":"IRCCS San Raffaele","startDate":"2024-03-01","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":10000},{"nctId":"NCT06176599","phase":"NA","title":"Clinical Study on the Treatment of Diabetic Kidney Disease With Shenxiao Yuning Decoction With Syndrome of Qi and Yin Deficiency and Blood Stasis","status":"UNKNOWN","sponsor":"Lin Liao","startDate":"2022-09-01","conditions":"Diabetic Kidney Disease","enrollment":60},{"nctId":"NCT04825795","phase":"","title":"DPP4 Inhibitor and Coronary Atherosclerosis in Patients Receiving Insulin Therapy","status":"COMPLETED","sponsor":"The Catholic University of Korea","startDate":"2010-01-01","conditions":"Diabetes Mellitus","enrollment":4007},{"nctId":"NCT04663282","phase":"PHASE2","title":"A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral Antidiabetics","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-02-04","conditions":"Type 2 Diabetes","enrollment":179},{"nctId":"NCT05591235","phase":"PHASE3","title":"Effect of Metformin, Dapagliflozin, Combination of Metformin and Pioglitazone in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2022-11","conditions":"Type2diabetes, Insulin Resistance","enrollment":60},{"nctId":"NCT05167513","phase":"PHASE4","title":"Monitoring Parameters Beyond Glycemic Control: Impact of Sitagliptin on Quality of Life in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Getz Pharma","startDate":"2021-01-01","conditions":"Quality of Life, Type 2 Diabetes, Metformin+Sitagliptin","enrollment":188},{"nctId":"NCT02967211","phase":"PHASE4","title":"A \"Real World\" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to \"Standard of Care\" Basal Insulin in Patients Already Using Basal Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-12-21","conditions":"Diabetes Mellitus, Type 2","enrollment":609},{"nctId":"NCT02855684","phase":"PHASE3","title":"Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-08-24","conditions":"Type 2 Diabetes Mellitus","enrollment":604},{"nctId":"NCT03011775","phase":"PHASE4","title":"Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease","status":"COMPLETED","sponsor":"Ukrainian Medical Stomatological Academy","startDate":"2012-11","conditions":"Adverse Effect, Atherosclerosis, Coronary, Insulin Resistance Syndrome","enrollment":43},{"nctId":"NCT05271695","phase":"","title":"Effect of Dietary Inflammatory Index on Inflammatory Markers and Metabolic Parameters, in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Istanbul University","startDate":"2019-11-01","conditions":"Type 2 Diabetes, Dietary Inflammatory Index (DII), Inflammation","enrollment":150},{"nctId":"NCT03823339","phase":"","title":"A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab Emirates","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-01-29","conditions":"Diabetes Mellitus, Type 2","enrollment":300},{"nctId":"NCT04146155","phase":"PHASE4","title":"Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-05-01","conditions":"Type 2 Diabetes, Peripheral Vascular Disorder Due to Diabetes Mellitus","enrollment":200},{"nctId":"NCT02874313","phase":"PHASE4","title":"CPAP Effect on the Progression of Diabetic Retinopathy in Patients With Sleep Apnea","status":"COMPLETED","sponsor":"Hospital Universitario La Paz","startDate":"2016-08","conditions":"Diabetic Retinopathy, Sleep Apnea","enrollment":82},{"nctId":"NCT02488252","phase":"PHASE2, PHASE3","title":"Semi-individualised Chinese Medicine Treatment as an Adjuvant Management for Diabetic Nephropathy","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2015-07","conditions":"Diabetic Nephropathies","enrollment":148},{"nctId":"NCT04866667","phase":"","title":"Observational Study of ASCVD Risks of Type 2 Diabetes in East China","status":"UNKNOWN","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2021-05-01","conditions":"Type 2 Diabetes Mellitus, Arteriosclerotic Cardiovascular Disease, Liraglutide","enrollment":800},{"nctId":"NCT02372539","phase":"","title":"Glucose Variability in Cancer Patients Receiving Dexamethasone","status":"WITHDRAWN","sponsor":"University of Colorado, Denver","startDate":"2015-01","conditions":"Hyperglycemia, Cancer","enrollment":""},{"nctId":"NCT01084967","phase":"","title":"Genetics of Obesity in Chinese Youngs","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2009-03","conditions":"Obesity, Metabolic Syndrome","enrollment":8000},{"nctId":"NCT03751657","phase":"PHASE2","title":"A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-11-29","conditions":"Diabetes Mellitus, Type 2","enrollment":247},{"nctId":"NCT02846233","phase":"NA","title":"Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2016-08","conditions":"Type 2 Diabetes Mellitus","enrollment":22},{"nctId":"NCT03013985","phase":"PHASE4","title":"Glargine U300 Hospital Trial","status":"COMPLETED","sponsor":"Emory University","startDate":"2017-05-17","conditions":"Type 2 Diabetes","enrollment":247},{"nctId":"NCT02320721","phase":"PHASE3","title":"Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-01","conditions":"Type 2 Diabetes Mellitus","enrollment":1014},{"nctId":"NCT02043054","phase":"PHASE3","title":"Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2013-12-16","conditions":"Type 2 Diabetes Mellitus, Cardiovascular Disease","enrollment":90},{"nctId":"NCT04167410","phase":"NA","title":"Effect of Perioperative Glycemia Protocol on Glycemic Outcomes in Diabetic Patients Undergoing Abdominal Surgery","status":"COMPLETED","sponsor":"Saglik Bilimleri Universitesi Gulhane Tip Fakultesi","startDate":"2017-09-15","conditions":"Hyperglycemia, Perioperative Complication","enrollment":47},{"nctId":"NCT03665350","phase":"PHASE2","title":"Insulin Treatment in Diabetic Older People With Heart Failure.","status":"TERMINATED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2018-11-08","conditions":"Heart Failure, Diabetes Mellitus, Type 2","enrollment":10},{"nctId":"NCT03511885","phase":"","title":"EUROASPIRE V Survey on Cardiovascular Disease Prevention and Diabetes","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2016-08-23","conditions":"Cardiovascular Diseases, Coronary Heart Disease","enrollment":1736},{"nctId":"NCT02752113","phase":"PHASE3","title":"Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes","status":"COMPLETED","sponsor":"Institut für Pharmakologie und Präventive Medizin","startDate":"2016-04","conditions":"Diabetes Mellitus Type 2","enrollment":101},{"nctId":"NCT02455076","phase":"PHASE4","title":"Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2015-09","conditions":"Type 2 Diabetes","enrollment":150},{"nctId":"NCT02060383","phase":"PHASE4","title":"Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-05-23","conditions":"Cushing's Disease, Acromegaly","enrollment":249},{"nctId":"NCT02954692","phase":"PHASE4","title":"A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-11-30","conditions":"Type 2 Diabetes Mellitus","enrollment":112},{"nctId":"NCT02738151","phase":"PHASE4","title":"Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-05-19","conditions":"Diabetes Mellitus, Type 2","enrollment":929},{"nctId":"NCT02365233","phase":"PHASE4","title":"Fatty Liver Study in Patients With Type II Diabetes","status":"TERMINATED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2013-05-01","conditions":"Type II Diabetes, Nonalcoholic Fatty Liver","enrollment":5},{"nctId":"NCT03196154","phase":"","title":"Association Between Insulin Resistance and Beta Cell Function With HbA1C in Diabetics","status":"COMPLETED","sponsor":"Clinical Research Centre, Malaysia","startDate":"2017-08-01","conditions":"Diabetes Mellitus, Type 2","enrollment":255},{"nctId":"NCT02585778","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-10-23","conditions":"Hypercholesterolaemia","enrollment":517},{"nctId":"NCT02696941","phase":"PHASE1","title":"SGLT2 Inhibitors and Metformin on Metabolism and Non-Alcoholic SteatoHepatitis","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2016-02","conditions":"Non-alcoholic Fatty Liver Disease","enrollment":20},{"nctId":"NCT01790438","phase":"PHASE3","title":"A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-03","conditions":"Diabetes Mellitus, Type 2","enrollment":641},{"nctId":"NCT02642159","phase":"PHASE4","title":"Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-03-15","conditions":"Dyslipidemia","enrollment":413},{"nctId":"NCT01582451","phase":"PHASE3","title":"A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-05","conditions":"Diabetes Mellitus, Type 2","enrollment":466},{"nctId":"NCT00194896","phase":"NA","title":"Preferred Treatment of Type 1.5 Diabetes","status":"COMPLETED","sponsor":"University of Washington","startDate":"2000-02","conditions":"Type 2 Diabetes Mellitus","enrollment":64},{"nctId":"NCT03249506","phase":"","title":"Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-05-12","conditions":"Diabetes Mellitus, Type 2","enrollment":25358},{"nctId":"NCT03253562","phase":"PHASE4","title":"Metformin Versus Vildagliptin for Diabetic Hypertensive Patients","status":"COMPLETED","sponsor":"MTI University","startDate":"2017-02-01","conditions":"Reducing the Elevated Blood Pressure for Diabetic Hypertensive Patients","enrollment":120},{"nctId":"NCT02182895","phase":"PHASE4","title":"Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2014-07","conditions":"Diabetes Mellitus","enrollment":72},{"nctId":"NCT01232491","phase":"PHASE4","title":"Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-10-29","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":611},{"nctId":"NCT00835861","phase":"PHASE2","title":"Effectiveness of Metformin Compared to Insulin in Pregnant Women With Mild Preexisting or Early Gestational Diabetes","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2008-08","conditions":"Non Insulin Dependent Diabetes, Pregnancy","enrollment":31},{"nctId":"NCT01798706","phase":"PHASE3","title":"Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Type 2 Diabetes","enrollment":350},{"nctId":"NCT03061851","phase":"NA","title":"The Individualized Behavioral Intervention of Smartphone App in the Treatment of Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Qingdao Zhixin Health Technology Co., Ltd.","startDate":"2017-01-25","conditions":"Diabetes Mellitus, Type 2","enrollment":400},{"nctId":"NCT02140645","phase":"","title":"Ascertainment of EMR-based Clinical Covariates Among Patients Receiving Oral and Non-insulin Injected Hypoglycemic Therapy","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-05","conditions":"Diabetes Mellitus, Type 2","enrollment":166613},{"nctId":"NCT01536600","phase":"","title":"Observational Study of Biphasic Insulin Aspart 30 Alone or in Combination With Oral Hypoglycaemic Agents in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":33010},{"nctId":"NCT00842192","phase":"","title":"An Observational Study in Type 2 Diabetic Patients on Oral Antidiabetic Drugs and Basal Insulin in Near East Countries","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":2155},{"nctId":"NCT02956655","phase":"NA","title":"Effect of Fasting Therapy on Blood Glucose Control and Islet Function in Newly Diagnosed Type 2 Diabetic Patients","status":"UNKNOWN","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2016-07","conditions":"Type 2 Diabetes Mellitus","enrollment":60},{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":1417914},{"nctId":"NCT00806936","phase":"","title":"Observational Study to Investigate the Efficacy and Safety of Human Insulin or Insulin Analogue Treatments in Type 2 Diabetes Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-12","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":4847},{"nctId":"NCT02610530","phase":"","title":"Surgical Intervention for the Treatment of Diabetes in Overweight Non-responders-1","status":"UNKNOWN","sponsor":"Turkish Metabolic Surgery Foundation","startDate":"2015-12","conditions":"Overweight, Diabetes Mellitus, Type 2","enrollment":90},{"nctId":"NCT01040819","phase":"PHASE4","title":"Does Pioglitazone Increase the Production of 15-EPI-Lipoxin A4?","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2010-02","conditions":"Type 2 Diabetes Mellitus","enrollment":25},{"nctId":"NCT02793505","phase":"","title":"Safety of Metformin in Pregnancy","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2014-01","conditions":"Pregnancy, Pregestational Diabetes, Polycystic Ovary Syndrom","enrollment":950},{"nctId":"NCT00579150","phase":"","title":"Exenatide Pregnancy Registry - Type 2 Diabetes in Pregnancy","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2009-01","conditions":"Birth Defects, Type 2 Diabetes, Preterm Birth","enrollment":7},{"nctId":"NCT02456428","phase":"","title":"Incretin-based Drugs and the Risk of Heart Failure","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Type 2 Diabetes Mellitus","enrollment":1499650},{"nctId":"NCT01676220","phase":"PHASE3","title":"Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-08","conditions":"Type 2 Diabetes Mellitus","enrollment":878},{"nctId":"NCT01077323","phase":"","title":"A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-09","conditions":"Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies), Healthy Subjects (Treated With no Diabetes Therapies)","enrollment":363766},{"nctId":"NCT01213784","phase":"PHASE2","title":"Optimized Glycemic Control in Heart Failure Patients With DM2:\"Effect on Left Ventricular Function and Skeletal Muscle\"","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2010-09","conditions":"Type 2 Diabetes, Heart Failure","enrollment":40},{"nctId":"NCT01910194","phase":"PHASE2","title":"Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying","status":"COMPLETED","sponsor":"Profil Institut für Stoffwechselforschung GmbH","startDate":"2013-12","conditions":"Diabetes Mellitus","enrollment":39},{"nctId":"NCT01668485","phase":"PHASE4","title":"Mechanisms of Glucose Counterregulation in Pancreatic Islet Transplantation","status":"COMPLETED","sponsor":"University of Giessen","startDate":"2001-11","conditions":"Type 1 Diabetes Mellitus","enrollment":36},{"nctId":"NCT01076842","phase":"PHASE4","title":"Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-04","conditions":"Diabetes Type 2","enrollment":75},{"nctId":"NCT01206712","phase":"","title":"Beta Cell Relieving and Cardiovascular Protective Effects of LANTUS Treatment in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"ikfe-CRO GmbH","startDate":"2009-11","conditions":"Diabetes Mellitus, Type 2","enrollment":106},{"nctId":"NCT00768365","phase":"","title":"Cardiovascular Risk in Patients With Non-Functional Adrenal Incidentaloma","status":"COMPLETED","sponsor":"Istanbul University","startDate":"2007-10","conditions":"Adrenal Cortex Neoplasms","enrollment":105}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Non-insulin antihyperglycemic therapy"],"phase":"phase_3","status":"active","brandName":"Non-insulin antihyperglycemic drugs","genericName":"Non-insulin antihyperglycemic drugs","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Non-insulin antihyperglycemic drugs lower blood glucose through mechanisms other than insulin replacement, such as enhancing insulin secretion, improving insulin sensitivity, or reducing hepatic glucose production. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}